These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 19275514)

  • 21. Targeted therapies in metastatic renal cancer in 2009.
    Bastien L; Culine S; Paule B; Ledbai S; Patard JJ; de la Taille A
    BJU Int; 2009 May; 103(10):1334-42. PubMed ID: 19338565
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
    Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Progress in the management of advanced renal cell carcinoma (RCC).
    Tong TQ; Rohde D; Peter S
    Aktuelle Urol; 2010 Jan; 41 Suppl 1():S57-60. PubMed ID: 20094957
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.
    Thompson Coon J; Hoyle M; Green C; Liu Z; Welch K; Moxham T; Stein K
    Health Technol Assess; 2010 Jan; 14(2):1-184, iii-iv. PubMed ID: 20028613
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Effect of angiogenesis inhibitors on renal cell carcinoma].
    Bodrogi I
    Magy Onkol; 2007; 51(2):145-53. PubMed ID: 17660871
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Recent advancements in the treatment of renal cell carcinoma--focus on international guidelines].
    Biró K; Küronya Z
    Magy Onkol; 2010 Dec; 54(4):369-76. PubMed ID: 21163768
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany].
    Bolenz C; Trojan L; Honeck P; Schöppler G; Herrmann E; Alken P; Michel MS; Häcker A
    Aktuelle Urol; 2009 Jan; 40(1):31-6. PubMed ID: 19177319
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies.
    Ravaud A
    Oncologist; 2011; 16 Suppl 2(Suppl 2):32-44. PubMed ID: 21346038
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sunitinib, sorafenib, temsirolimus or bevacizumab in the treatment of metastatic renal cell carcinoma: a review of health economic evaluations.
    Norum J; Nieder C; Kondo M
    J Chemother; 2010 Apr; 22(2):75-82. PubMed ID: 20435564
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
    Fernández-Pello S; Hofmann F; Tahbaz R; Marconi L; Lam TB; Albiges L; Bensalah K; Canfield SE; Dabestani S; Giles RH; Hora M; Kuczyk MA; Merseburger AS; Powles T; Staehler M; Volpe A; Ljungberg B; Bex A
    Eur Urol; 2017 Mar; 71(3):426-436. PubMed ID: 27939075
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeted therapy for metastatic renal cell carcinoma.
    Patel PH; Chaganti RS; Motzer RJ
    Br J Cancer; 2006 Mar; 94(5):614-9. PubMed ID: 16465192
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Novelties in the treatment for advanced renal-cell cancer].
    Maráz A
    Orv Hetil; 2011 Apr; 152(17):655-62. PubMed ID: 21464023
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Interdisciplinary recommendations on targeted therapy in the treatment of renal cell carcinoma].
    Miller K; Bergmann L; Albers P; Jäger E; Jakse G; Geschwend JE; Marschner N
    Aktuelle Urol; 2007 Jul; 38(4):328-30. PubMed ID: 17647172
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
    Golshayan AR; George S; Heng DY; Elson P; Wood LS; Mekhail TM; Garcia JA; Aydin H; Zhou M; Bukowski RM; Rini BI
    J Clin Oncol; 2009 Jan; 27(2):235-41. PubMed ID: 19064974
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An update on the medical therapy of advanced metastatic renal cell carcinoma.
    Kruck S; Merseburger AS; Gakis G; Kramer MW; Stenzl A; Kuczyk MA
    Scand J Urol Nephrol; 2008; 42(6):501-6. PubMed ID: 18615363
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer.
    Bellmunt J; Calvo E; Castellano D; Climent MA; Esteban E; García del Muro X; González-Larriba JL; Maroto P; Trigo JM
    Cancer Chemother Pharmacol; 2009 Mar; 63 Suppl 1():S1-13. PubMed ID: 19259675
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel agents for renal cell carcinoma require novel selection paradigms to optimise first-line therapy.
    Schmidinger M; Zielinski CC
    Cancer Treat Rev; 2009 May; 35(3):289-96. PubMed ID: 19232474
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions.
    Chowdhury S; Matrana MR; Tsang C; Atkinson B; Choueiri TK; Tannir NM
    Hematol Oncol Clin North Am; 2011 Aug; 25(4):853-69. PubMed ID: 21763971
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Signaling inhibitors in metastatic renal cell carcinoma.
    Escudier B
    Cancer J; 2008; 14(5):325-9. PubMed ID: 18836338
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tolerability of first-line therapy for metastatic renal cell carcinoma.
    Porta C; Szczylik C
    Cancer Treat Rev; 2009 May; 35(3):297-307. PubMed ID: 19249157
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.